Ortega-Legaspi, J., Morris, A., Flattery, M., Alexy, T., Devore, A., Maharaj, V., … Cole, R. T. (2021). Efficacy of 3 Months vs. 6 Months of Valganciclovir Prophylaxis for Heart Transplant Recipients at Intermediate Risk (R plus ) for CMV Complications. In JOURNAL OF HEART AND LUNG TRANSPLANTATION (Vol. 40, pp. S116–S117).

Ortega-Legaspi, J., A. Morris, M. Flattery, T. Alexy, A. Devore, V. Maharaj, C. Martin, et al. “Efficacy of 3 Months vs. 6 Months of Valganciclovir Prophylaxis for Heart Transplant Recipients at Intermediate Risk (R plus ) for CMV Complications.” In JOURNAL OF HEART AND LUNG TRANSPLANTATION, 40:S116–17, 2021.

Ortega-Legaspi J, Morris A, Flattery M, Alexy T, Devore A, Maharaj V, et al. Efficacy of 3 Months vs. 6 Months of Valganciclovir Prophylaxis for Heart Transplant Recipients at Intermediate Risk (R plus ) for CMV Complications. In: JOURNAL OF HEART AND LUNG TRANSPLANTATION. 2021. p. S116–7.

Ortega-Legaspi, J., et al. “Efficacy of 3 Months vs. 6 Months of Valganciclovir Prophylaxis for Heart Transplant Recipients at Intermediate Risk (R plus ) for CMV Complications.” JOURNAL OF HEART AND LUNG TRANSPLANTATION, vol. 40, no. 4, 2021, pp. S116–17.

Ortega-Legaspi J, Morris A, Flattery M, Alexy T, Devore A, Maharaj V, Martin C, Maziarz E, Cooper L, Shah K, Molina M, Udeshi E, Shah P, Cole RT. Efficacy of 3 Months vs. 6 Months of Valganciclovir Prophylaxis for Heart Transplant Recipients at Intermediate Risk (R plus ) for CMV Complications. JOURNAL OF HEART AND LUNG TRANSPLANTATION. 2021. p. S116–S117.